Sativex® in multiple sclerosis spasticity: A cost-effectiveness model

Keyphrases

• Sativex 100%
• Multiple Sclerosis Spasticity 100%
• Cost-effectiveness Model 100%
• Multiple Sclerosis 66%
• Spasticity 50%
• Quality-adjusted Life Years 33%
• Disability 16%
• Spain 16%
• Germany 16%
• Cost-effectiveness 16%
• Standard of Care 16%
• Endocannabinoid System 16%
• Treatment Options 16%
• Acquisition Cost 16%
• Physiotherapy 16%
• Low Severity 16%
• Tetrahydrocannabinol 16%
• Progressive Disease 16%
• Chronic Progressive 16%
• Markov Model 16%
• Cost-effective Treatment 16%
• Incremental Cost-effectiveness Ratio 16%
• Incremental Cost 16%
• Spasm 16%
• Model-based Analysis 16%
• Payer Perspective 16%
• Socioeconomic Burden 16%
• Expert Review 16%
• Oromucosal Spray 16%
• Cannabidiol 16%
• Spasticity Treatment 16%
• Add-on Medications 16%
• Reduced Resource Consumption 16%
• Healthcare Payer 16%

Medicine and Dentistry

• Multiple Sclerosis 100%
• Spasticity 100%
• Nabiximols 100%
• Cost-Effectiveness Analysis 100%
• Health Care Cost 42%
• Quality Adjusted Life Year 28%
• Physiotherapy 14%
• Endocannabinoid System 14%
• Muscle Spasm 14%
• Progressive Disease 14%
• Base 14%
• Effective Treatment 14%
• Treatment Option 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Multiple Sclerosis 100%
• Spasticity 100%
• Nabiximols 100%
• Base 14%
• Muscle Spasm 14%
• Endocannabinoid System 14%
• Diseases 14%